Retatrutide 15mg
Longevity
$189
Triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors. Research-grade retatrutide for metabolic optimization, body composition, and energy regulation.
Overview
Retatrutide is a next-generation triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. In clinical trials it demonstrated superior weight loss outcomes compared to dual agonists, with Phase 2 data showing up to 24% reduction in body weight over 48 weeks. Its glucagon receptor activity provides additional energy expenditure benefits beyond GLP-1 alone.
Lab Results — 15mg
Every batch is independently tested. Results below are from the Certificate of Analysis for the 15mg batch.
Certificate of Analysis
Scientific Details
Molecular Formula
C₂₂₄H₃₅₆N₅₆O₆₈S₂
Molecular Weight
~4.9 kDa
Form
Lyophilized peptide powder
Solubility
Soluble in bacteriostatic water
Dosage Range
0.5–12mg weekly (research context)
Plasma Half-Life
~6 days
Bioavailability
~90% subcutaneous
Resources
Key peer-reviewed studies supporting the efficacy and safety of this compound.
Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial
Jastreboff A.M. et al. — New England Journal of Medicine (2023)
Key FindingRetatrutide produced up to 24.2% mean weight reduction at 48 weeks, the highest reported for any obesity pharmacotherapy to date.
Glucagon receptor agonism in metabolic disease
Day J.W. et al. — Nature Chemical Biology (2009)
Key FindingCombined GLP-1/glucagon receptor activation produced greater fat loss and metabolic improvement than GLP-1 alone in preclinical models.
GIP and GLP-1 receptor co-agonism for weight management
Finan B. et al. — Science Translational Medicine (2013)
Key FindingDual incretin receptor agonism demonstrated synergistic reductions in body weight and improved insulin sensitivity versus monotherapy.